Cor Vasa 2010, 52(11-12):706-712 | DOI: 10.33678/cor.2010.176

Danon disease - a disorder of autophagy as a cause of hypertrophic cardiomyopathy

Miloš Kubánek1,*, Milan Elleder2, Jakub Sikora2,3, Marek Šramko1, Jana Malušková3, Lenka Dvořáková2, Hana Vlášková2, Martin Kotrč1, Jana Vrbská1, Petr Ridzoň4, Michal Šnorek5, František Toušek5, Ivan Málek1, Jan Pirk6
1 Klinika kardiologie, Institut klinické a experimentální medicíny, Praha
2 Ústav dědičných a metabolických poruch, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha
3 Oddělení klinické a transplantační patologie, Institut klinické a experimentální medicíny, Praha
4 Neurologická klinika, Fakultní Thomayerova nemocnice, Praha
5 Kardiologické oddělení, Nemocnice České Budějovice, a. s., České Budějovice
6 Klinika kardiovaskulární chirurgie, Institut klinické a experimentální medicíny, Praha, Česká republika

Danon disease is an X-linked disorder caused by a mutation of lysosomal-associated membrane protein 2 (LAMP2). Clinically, the disorder manifests itself mainly as hypertrophic cardiomyopathy, skeletal muscle myopathy or, alternatively, as liver disease. In women, its presentation in organs and severity of the disorder are modified by X-inactivation. The aim of our study was to report the first case of a family with Danon disease diagnosed in the Czech Republic. The diagnosis was initially established in a 27-year-old man with end-stage heart failure secondary to hypetrophic cardiomyopathy and, subsequently, also in the patient's sister and nephew. The diagnosis was based on evidence of an autophagic process in a skeletal muscle biopsy specimen, immunohistochemically demonstrated absence of LAMP2, and evidence of a pathogenic mutation in the respective gene. Findings reported by cardiologists were consistent with the diagnosis of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction, and EKG showing signs of preexcitation. The disorder manifested itself clinically when the patient was 10 years old (and his sister and nephew aged 12 and 8 years, respectively). The patient and his sister were shown to develop left ventricular systolic dysfunction and progression to end-stage heart failure in their thirties. Their condition was successfully managed by heart transplantation. The skeletal muscle involvement in both patients was reflected in increased serum creatine kinase levels.

Keywords: Hypertrophic cardiomyopathy; Danon disease; LAMP2

Published: November 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubánek M, Elleder M, Sikora J, Šramko M, Malušková J, Dvořáková L, et al.. Danon disease - a disorder of autophagy as a cause of hypertrophic cardiomyopathy. Cor Vasa. 2010;52(11-12):706-712. doi: 10.33678/cor.2010.176.
Download citation

References

  1. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:21-32. Go to original source... Go to PubMed...
  2. Kettner J. Hypetrofická kardiomyopatie. In: Vojáček J, Kettner J, eds. Klinická kardiologie. Hradec Králové: Nucleus HK, 2009:452-462.
  3. Bultas J. Srdce a metabolická onemocnění. In: Vojáček J, Kettner J, eds. Klinická kardiologie. Hradec Králové: Nucleus HK, 2009:856-865.
  4. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846. Go to original source... Go to PubMed...
  5. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-372. Go to original source... Go to PubMed...
  6. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981;31:51-57. Go to original source... Go to PubMed...
  7. Nishino I, Fu J, Tamji, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406: 906-910. Go to original source... Go to PubMed...
  8. Fanin M, Nascimeni AC, Fulizio L, et al. Generalised lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 2006;168:1309-1320. Go to original source... Go to PubMed...
  9. Regelsberger G, Höftberger R, Pickl WF, et al. Danon disease: Case report and detection of new mutation. J Inherit Metab Dis 2009 Jul 7. [Epub ahead of print] Go to original source... Go to PubMed...
  10. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-1259. Go to original source... Go to PubMed...
  11. Toib A, Grange DK, Kozel BA, et al. Distinct clinical and histological presentations of Danon cardiomyopathy in young women. J Am Coll Cardiol 2010;55:408-410. Go to original source... Go to PubMed...
  12. Prall FR, Drack A, Tailor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology 2006;113:1010-1013. Go to original source... Go to PubMed...
  13. Huynh KK, Eskelinen EL, Scott CC, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 2007;26:313-324. Go to original source... Go to PubMed...
  14. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy - Heart Failure Society of America Practice Guidelines. J Card Fail 2009;15:83-97. Go to original source... Go to PubMed...
  15. Colombo MG, Botto N, Vittorini S, et al. Clinical utility of genetic testing for inherited hypertrophic and dilated cardiomyopathies. Card Ultrasound 2008;6:62. Go to original source... Go to PubMed...
  16. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-211. Go to original source... Go to PubMed...
  17. Čurila K, Pěnička M, Línková H, et al. Molekulární genetika u hypertrofické kardiomyopatie. Cor Vasa 2007;49:138-142. Go to original source...
  18. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006;81:459-467. Go to original source... Go to PubMed...
  19. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83;630-638. Go to original source...
  20. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010;121:445-456. Go to original source... Go to PubMed...
  21. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009;302:2471-2476. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.